Phase 1 Clinical Trials
Clinilabs Drug Development Corporation provides a full range of CNS Phase 1 capabilities, with extensive expertise and experience in all the early phase studies (below) required for regulatory approval. We prioritize and support early stage development programs with access to 100 early-phase beds, enabling our customers to move their promising new chemical entities from proof-of-concept to pivotal trials faster.
First in human
First in class
Single ascending dose (SAD)
Multiple ascending dose (MAD)
Bioequivalence (BE)
Drug – drug interaction studies
Drug – alcohol interactions studies
Food effect studies
Pharmacokinetic (PK) studies
Pharmacodynamic (PD) studies
Kinetic-dynamic relationships
There is so much more to be done; the patients are waiting.
– Dr. Paul Janssen